205 related articles for article (PubMed ID: 38456165)
1. Temporal trends in HCV treatment uptake and success among people who inject drugs in Baltimore, MD since the introduction of direct acting antivirals.
Coyle CR; Gicquelais RE; Genberg BL; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH
Drug Alcohol Depend; 2023 Dec; 253():. PubMed ID: 38456165
[TBL] [Abstract][Full Text] [Related]
2. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
3. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
[TBL] [Abstract][Full Text] [Related]
4. Geographic variation in HCV treatment penetration among people who inject drugs in Baltimore, MD.
Coyle CR; Desjardins MR; Curriero FC; Rudolph J; Astemborski J; Falade-Nwulia O; Kirk GD; Thomas DL; Mehta SH; Genberg BL
J Viral Hepat; 2023 Oct; 30(10):810-818. PubMed ID: 37382024
[TBL] [Abstract][Full Text] [Related]
5. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019.
Requena MB; Protopopescu C; Stewart AC; van Santen DK; Klein MB; Jarrin I; Berenguer J; Wittkop L; Salmon D; Rauch A; Prins M; van der Valk M; Sacks-Davis R; Hellard ME; Carrieri P; Lacombe K;
Int J Drug Policy; 2024 Feb; 124():104311. PubMed ID: 38184902
[TBL] [Abstract][Full Text] [Related]
6. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study.
Malme KB; Ulstein K; Finbråten AK; Wüsthoff LEC; Kielland KB; Hauge J; Dalgard O; Midgard H
Int J Drug Policy; 2023 Jun; 116():104044. PubMed ID: 37149914
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era.
Falade-Nwulia O; Gicquelais RE; Astemborski J; McCormick SD; Kirk G; Sulkowski M; Thomas DL; Mehta SH
Liver Int; 2020 Oct; 40(10):2407-2416. PubMed ID: 32770638
[TBL] [Abstract][Full Text] [Related]
9. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
[TBL] [Abstract][Full Text] [Related]
10. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
[TBL] [Abstract][Full Text] [Related]
11. Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.
Corcorran MA; Tsui JI; Scott JD; Dombrowski JC; Glick SN
Drug Alcohol Depend; 2021 Mar; 220():108525. PubMed ID: 33461152
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users.
Hsu JT; Hsu PI; Shie CB; Chuah SK; Wu IT; Huang WW; Tang SY; Tsai KF; Kuo LF; Ghose S; Hsu JC; Shih CA
Medicina (Kaunas); 2022 Mar; 58(3):. PubMed ID: 35334612
[TBL] [Abstract][Full Text] [Related]
13. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
[TBL] [Abstract][Full Text] [Related]
14. HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs.
Martinello M; Hajarizadeh B; Grebely J; Dore GJ; Matthews GV
Curr HIV/AIDS Rep; 2017 Jun; 14(3):110-121. PubMed ID: 28432579
[TBL] [Abstract][Full Text] [Related]
15. Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
Mora M; Goodyear T; Marcellin F; Shoveller J; Di Beo V; Calzolaio C; Sogni P; Wittkop L; Zucman D; Poizot-Martin I; Lacombe K; Salmon-Céron D; Knight R; Carrieri P
J Viral Hepat; 2020 Dec; 27(12):1462-1472. PubMed ID: 32810905
[TBL] [Abstract][Full Text] [Related]
16. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
Tatara E; Gutfraind A; Collier NT; Echevarria D; Cotler SJ; Major ME; Ozik J; Dahari H; Boodram B
PLoS One; 2022; 17(3):e0264983. PubMed ID: 35271634
[TBL] [Abstract][Full Text] [Related]
17. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
[TBL] [Abstract][Full Text] [Related]
18. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?
Panagiotoglou D; Krebs E; Min JE; Olding M; Ahamad K; Ti L; Montaner JSG; Nosyk B
Int J Drug Policy; 2017 Sep; 47():169-176. PubMed ID: 28578865
[TBL] [Abstract][Full Text] [Related]
19. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
Iversen J; Wand H; McManus H; Dore GJ; Maher L
Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
[TBL] [Abstract][Full Text] [Related]
20. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.
Taylor LE; Swan T; Matthews GV
Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S118-24. PubMed ID: 23884059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
